The RSV vaccine protects against RSV (respiratory syncytial virus), a common seasonal virus that infects the nose, throat, and lungs. While RSV typically causes mild, cold-like symptoms, it can lead ...
Palivizumab, which is administered in monthly doses during the RSV season, is no longer routinely recommended and will be discontinued on December 31, 2025. The American Academy of Pediatrics (AAP) ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. This electron microscope image provided by the ...
RSV vaccines were 58% effective at preventing RSV-associated hospitalizations among adults age 60 or older across two seasons. Vaccine effectiveness against all-cause cardiorespiratory ...
The FDA is reviewing RSV vaccines, which have drastically lowered infant hospitalizations, a spokesperson confirmed US regulatory officials are re-examining the safety of RSV shots despite no ...
Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. The U.S. Food and Drug Administration building is ...
The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations to face scrutiny under Health Secretary Robert F. Kennedy Jr. No safety ...
US officials held calls with drugmakers' senior executives about safety Scrutiny follows seizure concerns raised by vaccine skeptics RSV therapies shown to reduce infant hospitalizations Companies say ...
The FDA is examining the safety of shots that protect infants from respiratory syncytial virus (RSV), according to a report from Reuters. The agency has notified executives at AstraZeneca, Merck and ...
U.S. health officials are reportedly questioning the safety of several approved therapies to treat respiratory syncytial virus (RSV) in babies. The treatments—specifically, Sanofi and AstraZeneca’s ...
U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback